Cabaletta Bio (CABA)
Develops engineered T-cell therapies for autoimmune disease, prioritizing rese-cel.
Something off on this page? Send us feedback.
A Philadelphia clinical-stage biotech focusing its CARTA platform on rese-cel, an investigational CD19-CAR T therapy in the multi-indication RESET program.
Built around engineered T-cell approaches to autoimmune disease, the CABA platform has two strategies: CARTA and CAART. CARTA is being prioritized around rese-cel, formerly CABA-201, a fully human CD19-CAR T investigational therapy evaluated in the multi-indication RESET program. That program spans a range of autoimmune disease settings in rheumatology, neurology, and dermatology.
Headquarters and laboratories are in Philadelphia. The scientific origin traces to a University of Pennsylvania collaboration combining autoimmune-disease research with CAR-T design. Development depends on clinical progress, regulatory alignment, manufacturing, and external capital because the therapies remain investigational.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Dec 20, 2024 | Evercore ISI Group | Downgrade | ||
| Dec 19, 2024 | Wells Fargo | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $225.1M · Total debt $25.7M · Total assets $256.7M · Shareholders' equity $210.6M
- Revenue
- $0
- Operating income
- −$52.0M
- Net income
- −$51.0M
No dividends on record.
| Institutions | ≈ 93.04% | 157.75M shares | |
|---|---|---|---|
| 151 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.14% | 244.2K shares | |
| 7 holders · as of Jan 21, 2026 | |||
| Other | ≈ 6.82% | 11.55M shares | |
| remainder | |||
169.55M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jennison Associates LLCInstitution | 11.82% | 20.03M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 11.13% | 18.87M | as of Jun 30, 2026 |
Bain Capital Life Sciences Investors, LLCInstitution | 10.17% | 17.24M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.34% | 10.75M | as of Jun 30, 2026 |
Adage Capital Partners GP, L.L.C.Institution | 5.41% | 9.17M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 21, 2026 | Michael Gerard | officer: General Counsel | +6,600 | $2.27 |
| Jan 21, 2026 | Mark Simon | director | +11,061 | $2.28 |
| Jan 21, 2026 | Steven Nichtberger | director, officer: President & CEO | +45,000 | $2.24 |
| Jan 21, 2026 | Catherine Bollard | director | +4,405 | $2.27 |
| Jan 21, 2026 | Steve Gavel | officer: Chief Commercial Officer | +22,170 | $2.27 |
- Kyverna Therapeutics
Autologous CD19 CAR-T program for B-cell-driven autoimmune disease
- Cartesian Therapeutics
Autologous CAR-T in myasthenia gravis and myositis
- Bristol-Myers Squibb
CD19 CAR-T program for refractory lupus, systemic sclerosis, and myositis
- Fate
Off-the-shelf CD19 CAR-T in lupus, sclerosis, and myositis
- AstraZeneca (ADR)
Dual-target BCMA/CD19 CAR-T program for refractory lupus
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cabaletta Bio | $2.52 | +2.44% | $401.1M | — | — | — | — |
| Kyverna Therapeutics | $7.54 | +5.90% | $432.9M | — | — | — | — |
| Cartesian Therapeutics | $8.12 | +2.23% | $233.3M | — | — | 157.9 | −45.0% |
| Bristol-Myers Squibb | $62.54 | −0.13% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Fate | $2.57 | +1.38% | $294.9M | — | — | 45.4 | +9.2% |
| AstraZeneca (ADR) | $168.18 | +0.05% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Median | 19.5 | 12.8 | 24.8 | +6.1% |